Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nanalysis Scientific ( (TSE:NSCI) ) has issued an update.
Nanalysis Scientific Corp. has announced the acceptance of its first regulated assay for pharmaceutical quality control via benchtop NMR by the United States Pharmacopeia and European Pharmacopeia. This development marks a significant step in the company’s strategy to proliferate benchtop NMR technology across industrial quality control sectors, overcoming previous limitations of traditional NMR technology. The acceptance of the assay for hydroxypropyl betadex, a key pharmaceutical excipient, highlights Nanalysis’ efforts to modernize and digitalize quality control methods, potentially expanding its market presence and offering new opportunities for stakeholders.
More about Nanalysis Scientific
Nanalysis Scientific Corp. operates in two primary business segments: Scientific Equipment and Security Services. The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers for laboratory and industrial markets, with products used across various industries such as oil and gas, chemical, mining, pharma, and more. It has a strong innovation pipeline and has expanded into security services, providing maintenance for airport security equipment in Canada.
Average Trading Volume: 88,584
Technical Sentiment Signal: Sell
Current Market Cap: C$27.56M
For detailed information about NSCI stock, go to TipRanks’ Stock Analysis page.